Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. November 2015 07:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Conduct Phase III Clinical Trial for PRX-102 for the Treatment of Fabry Disease Following a Successful End-of-Phase II Meeting With FDA

Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head...
09. November 2015 16:05 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Third Quarter 2015 Financial Results

Net losses narrowed Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product...
19. Oktober 2015 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters...
13. Oktober 2015 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Sells Its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a Total of $46 Million

Protalix to Use Funds to Aggressively Push Its Clinical Pipeline Forward and Execute Its New Strategy of Developing Clinically Superior Biologics Protalix Receives All Rights to ELELYSO in...
05. Oktober 2015 08:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH), a...
09. September 2015 07:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Positive efficacy data across all disease parameters Positive safety data with low level of antibody formation End of Phase II meeting with FDA scheduled before year end CARMIEL, Israel, Sept....
10. August 2015 16:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results

CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the second quarter of 2015. "We recently reported...
03. August 2015 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF

CARMIEL, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive clinical study results from the Company's Phase I trial of PRX-106,...
12. Juni 2015 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

CARMIEL, Israel, June 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic...
14. Mai 2015 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive Officer, will...

Vorherige Seite